Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 3Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Doxorubicin 4Cyclophosphamide 4fludarabine phosphate 3Vorinostat 3Vincristine 3Etoposide 3Rituximab 2Prednisone 2Pharmacogenomic Testing 2MK 2206 2Cyclosporine 2Busulfan 2Bortezomib 2Bevacizumab 2Antilymphocyte Serum 2veliparib 1vandetanib 1temsirolimus 1tanespimycin 1siplizumab 1romidepsin 1obatoclax 1liposomal doxorubicin 1gossypol acetic acid 1ganitumab 1fludarabine 1duvelisib 1cediranib 1cc-486 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Extranodal NK-T-Cell × Receptors, Chimeric Antigen × Clear all
NCT03049449 2023-01-18

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 19 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡